Multiple myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. VoseDonna Weber, Joachim Yahalom, Furhan Yunus

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

Original languageEnglish (US)
Pages (from-to)908-942
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number9
StatePublished - Oct 2009


  • Bisphosphonates
  • C-reactive protein
  • Combination chemotherapy
  • Cytogenetics
  • Immunomodulatory drugs
  • Multiple myeloma
  • NCCN Clinical Practice Guidelines
  • Novel therapies
  • Primary amyloidosis
  • Proteasome inhibitor
  • Stem cell transplant
  • Supportive therapies
  • Waldenström's monoclonal protein

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Multiple myeloma'. Together they form a unique fingerprint.

Cite this